Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema

NCT06957080 is registered in ClinicalTrials.gov with EyeBiotech Ltd. as lead sponsor.

NCT NCT06957080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06957080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema
Lead sponsor
EyeBiotech Ltd.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
April 16, 2025
Completion date
March 30, 2028
Enrollment
1,054 (actual)
Sites
164

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme)